Home > News > Breakthrough Pain in Cancer Patients— Pharmacologic Symptomatic Treatment
Supportive Cancer Care
Read Time: 11 mins

Breakthrough Pain in Cancer Patients— Pharmacologic Symptomatic Treatment

Published Online: June 3rd 2011 US Oncology & Hematology, 2011;7(1):17-21 DOI: https://doi.org/10.17925/OHR.2011.07.1.17
Authors: Marco Pappagallo
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Breakthrough pain is experienced by many cancer patients who are being treated with opioids for the management of chronic persistent pain. There is currently no ‘gold standard’ approach for the pharmacologic symptomatic treatment of breakthrough pain but proposed strategies include the implementation of primary therapies (e.g. chemotherapy, radiotherapy, and surgery) for the underlying cause of the pain; optimization of scheduled analgesia; use of adjuvants; and specific supplemental analgesia for breakthrough pain (the most common pharmacologic strategy). Individualization of treatment is important and a combination of these strategies may be required. In this article, pharmacotherapeutic approaches to managing breakthrough pain are discussed, including different routes of administration and newer opioid formulations. In addition, the current guidelines for managing breakthrough pain are examined. Acknowledgment: Writing support was provided by Touch Briefings. Support: The publication of this article was funded by ProStrakan. The views and opinions expressed are those of the author and not necessarily those of ProStrakan.

Keywords

Breakthrough pain, cancer, opioid, supplemental analgesia, background pain, quality of life

Article:

Breakthrough pain is a transitory flare of pain superimposed on an otherwise stable pain pattern in patients treated with opioids.1 Breakthrough pain is a common feature in patients with cancer and is associated with significant physical, psychologic and economic burdens on patients as well as their care-givers.2 The most common subtype of breakthrough pain is incident pain, which is due to movement and is commonly associated with bone metastases or fractures.2 Breakthrough pain can also be idiopathic and occur spontaneously, with no obvious precipitating event. Another type of breakthrough pain is the incident non-predictive pain that is precipitated by non-volitional factors (e.g. bladder spasm or coughing).2

The successful management of breakthrough pain may involve a number of different interventions. For some patients, optimization of around-the-clock (ATC) analgesia according to the World Health Organization (WHO) analgesic ladder will suffice in managing breakthrough pain. For the majority of patients, however, other avenues of pharmacotherapeutic treatments for breakthrough pain are needed. These include supplemental doses of analgesics, the most common pharmacologic treatment strategy for managing breakthrough pain. The goal of pharmacologic treatment of breakthrough pain is ultimately to reduce the intensity and frequency of pain episodes. In the current article, the pharmacotherapeutic approaches available for managing episodes of breakthrough pain will be discussed, focusing on the various opioid formulations and administration routes. Optimization of Around-the-clock Analgesia
In order to manage breakthrough pain, background pain should be effectively managed and controlled by ATC analgesics.3 The effectiveness of ATC treatment for background pain should be regularly assessed, with reassessment advised if breakthrough cancer pain incidence occurs more than four times per day.4 Optimizing the ATC analgesia according to the principles of the WHO analgesic ladder may help ameliorate breakthrough pain.5 According to the WHO ladder, a first step can be the oral administration of acetaminophen and/or non-steroidal anti-inflammatory drugs (NSAIDs). This is appropriate assuming that the pain is of mild intensity (4 or less on the 0–10 numeric rating scale) and there are no contraindications for organ toxicity or tolerability issues related to the use of such drugs. Studies have shown that effective management of background pain is possible with the use of NSAIDs,6 although there is no specific evidence in breakthrough pain.

If pain is not adequately reduced, in the absence of treatment-limiting side-effects an increase in the ATC opioid dose may be considered in an effort to reduce the frequency or intensity of breakthrough pain. Examples of potent opioid agonists used for managing background pain include:

  • transdermal fentanyl;
  • controlled-release oxycodone;
  • extended-release hydromorphone;
  • methadone, morphine (controlled-, sustained- and extended-release formulations); and
  • extended-release oxymorphone.

These drugs are characterized by a slow onset of action and their pharmacokinetic profiles have minimal peaks and troughs that result in stable blood levels over the dose period.7 Studies have shown that increasing the ATC opioid medication may result in improved background and breakthrough pain.8,9 Even though these studies are on a small scale, optimization of ATC opioid dose is a potential strategy for managing breakthrough pain, with the opioid dose being lowered again if the patient experiences adverse effects between episodes of breakthrough pain.10

Adjuvant Analgesics
In addition to these steps, the use of adjuvant drugs can be considered at all stages of the patient’s illness and at each step of the WHO analgesic ladder.11 Adjuvant analgesics are a diverse group of drugs that were originally developed for a primary indication other than pain. Many of these medications are currently used to enhance analgesia under specific circumstances. Of interest, a few of these agents are currently used as primary analgesics for specific pain conditions as well as adjuvants in some other pain conditions.12 Adjuvant analgesics (e.g. antidepressants, anticonvulsants, N-methyl-D-aspartic acid antagonists, corticosteroids, and topicals) can be administered alone, but they are usually accompanied by acetaminophen/NSAIDS and opioids.11 Adjuvant analgesics are widely used, especially for the relief of neuropathic cancer pain, which can present with a component of breakthrough pain.13,14

Supplemental Analgesia
The use of supplemental doses of analgesics is the cornerstone of pharmacologic treatment strategies for managing breakthrough pain. This type of medication is taken as required, rather than on a regular basis. The ideal supplementary analgesic should be efficacious, with a rapid onset, relatively short duration of action, and minimal adverse effects. It can be used either prophylactically, for predictable volitional incident pains or procedural pains, or at the onset of breakthrough pain for unpredictable spontaneous pain or non-volitional incident pains.2

Non-opioid analgesics and adjuvant analgesics have been used/ investigated as supplemental medication for episodes of breakthrough pain, but they typically have a slow onset and relatively long duration of action.15–17 For this reason, in the majority of cases the most appropriate supplemental medication will be an opioid analgesic. The most common method of providing supplemental medication is with oral short-acting formulations of morphine and other opioid analgesics. Despite their short-acting nature, the pharmacokinetic/pharmacodynamic profiles of these oral opioids (onset of action: 30–40 minutes; duration of effect: about four hours) do not tend to mirror the temporal characteristics of most breakthrough pain episodes.4 For this reason, these oral opioid formulations are most effective for predictable incident breakthrough pain, for which they can be given 30–45 minutes before a known triggering activity. Efforts to deliver rescue medication more effectively have explored alternatives to the oral route, including parenteral, rectal, inhaled, intranasal, sublingual, and oral transmucosal preparations.

Parenteral Opioids
The parenteral routes of opioid administration (intravenous and subcutaneous) have been shown to be effective, well tolerated, and safe for the management of breakthrough pain.18,19

The use of parenteral opioids is, however, associated with several disadvantages. For example, any indwelling intravenous catheter can become a site of infection and thus requires skilled nursing attention if the patient is unable to care for catheter access.20 In addition to this, more costs are involved as this route requires preparation of the opioid solution for injection by the pharmacist and administration of the infusion via an external pump.20 Despite this, the rapid onset of action associated with this route of administration means that it may be acceptable in cases where the breakthrough pain is severe.21

Oral Transmucosal Opioids
The oral transmucosal routes of administration (buccal and sublingual) have increasingly been used in the management of breakthrough pain episodes.22 The mouth provides a large mucosal surface for drug absorption, allowing drugs to enter the systemic circulation directly, bypassing the gastrointestinal tract and first-pass metabolism in the liver.

Fentanyl citrate, a synthetic opioid, has a rapid onset of effect and a short duration of action,23 matching the temporal characteristics of a breakthrough pain episode. Furthermore, its high lipophilicity makes a number of routes of administration feasible, including oral transmucosal. The US and European approval of oral transmucosal fentanyl citrate (OTFC), a lozenge impregnated with fentanyl designed to dissolve slowly in the mouth, was an important advance in breakthrough pain treatment. It provides a non-invasive method of administration and has demonstrated a faster onset of relief and greater degree of breakthrough pain relief than oral morphine.24,25 In addition, a Cochrane review confirmed the effectiveness of this modality for treating breakthrough pain and reported that OTFC produced faster/greater analgesia than oral morphine.22

A second oral transmucosal product with marketing authorization in the US and Europe is the effervescent buccal fentanyl tablet.26 This tablet provides rapid penetration of fentanyl through the buccal mucosa by using effervescence to cause pH shifts that enhance the rate and extent of fentanyl absorption. The efficacy of this formulation has been shown in placebo-controlled studies that demonstrated an analgesia onset that was faster than would be expected from oral therapy.27–30

Mucoadhesive film formulations of fentanyl for buccal or sublingual absorption aimed at rapid relief from breakthrough pain are also available. Fentanyl buccal soluble film (FBSF) is a transmucosal delivery system based on a polymer film. It delivers fentanyl across the mucosa in a pH-dependent manner.31 FBSF was shown to be efficacious and safe in a placebo-controlled study of breakthrough pain patients32 and has recently been approved in this setting in the US, Canada, and Europe. A sublingual tablet formulation of fentanyl that uses mucoadhesives to hold the fentanyl in contact with the mucosa has also been marketed in Europe and has recently received Food and Drug Administration (FDA) approval in the US. Sublingual fentanyl citrate comes as a rapidly disintegrating tablet consisting of an ordered mixture of fentanyl combined with soluble carrier particles that is rapidly absorbed.33 This formulation was tested in a randomized, placebo-controlled phase III trial in opioid-tolerant patients with breakthrough cancer pain. Here, sublingual fentanyl citrate provided significant improvements in pain intensity compared with placebo from 10 minutes post-administration. It was well-tolerated both systemically and sublingually.34Intranasal Opioids
The intranasal route is another option for achieving rapid uptake of opioids. It is currently being used/investigated to provide acute and breakthrough pain relief. The large absorptive surface area of the nasal mucosa is highly vascular and thus offers rapid absorption of drugs into the systemic circulation while bypassing gastrointestinal and hepatic pre-systemic metabolism.35 This route of administration may be more acceptable to patients who experience nausea, vomiting, oral mucositis, impaired gastrointestinal function, and xerostomia, for whom the oral route of administration may be difficult.

A potential disadvantage with the intranasal route is the relatively small volume of drug the nose is able to accommodate. The efficacy of intranasal fentanyl spray (INFS) was compared with that of OTFC for the relief of cancer-related breakthrough pain in an open-label trial.36 The difference in pain intensity was significantly greater for the INFS than OFTC from five minutes post-dosing. Clinically important pain relief (≥33% reduction in pain intensity) was seen five minutes after INFS treatment in a quarter of breakthrough pain episodes.

A second intranasal fentanyl formulation, fentanyl pectin nasal spray provided rapid analgesia and clinically meaningful pain relief (≥2 point decrease in pain intensity on a 0–10 numerical scale) versus placebo in a randomized, double-blind study in breakthrough cancer pain patients.37 IFNS and fentanyl pectin nasal spray were well-tolerated and patient acceptability of the intranasal formulations was high in both studies.36,37 Both INFS and OTFC are approved in Europe for the management of breakthrough pain. Other fentanyl formulations and devices for intranasal administration are currently being developed. These include an intranasal formulation of the fentanyl analog sufentanil, which was shown to be safe and effective in a prospective, open-label study of patients with cancer-related breakthrough pain.38

Inhaled Opioids
The lungs present a large surface area for drug absorption but there are limited data investigating the use of inhaled opioids in patients with breakthrough pain. This may be because the route has a number of limitations. It requires complex devices to create a mist prior to inhalation, as well as various types of nebulizers (depending on the patient).39

Rectal Opioids
Rectal administration of opioids offers the possible pharmacokinetic advantage of directly entering the systemic circulation via the lower rectal veins. It is also useful for patients who are unable to tolerate oral or parenteral routes due to bleeding disorders or generalized edema.40 Several types of rectal opioid preparations may be formulated, depending on the country and the acceptance of patients and care givers. In the US, compounding pharmacies can prepare opioid (e.g. hydromorphone) suppositories. The administered dose is usually the same as the oral dose.

Even though rectal administration can provide rapid pain relief, absorption rates are variable, and therefore the amount of pain relief can also vary for the doses administered.41 In a study of 100 patients with chronic cancer-related pain, patients were asked to complete a questionnaire concerning the acceptability of nine administration routes. The rectal route was the least acceptable.21The decision to use a specific opioid preparation should be based on a combination of:

  • the pain characteristics (onset and duration);
  • the product characteristics (pharmacokinetics and pharmacodynamics);
  • the patient’s previous response to opioids (efficacy and tolerability); and particularly
  • the patient’s preference for an individual preparation.

Dosing of Supplemental Opioid Analgesia
Traditionally, based largely on anecdotal experience, is has been advised that a supplemental opioid dose roughly equivalent to 5–10% of the total opioid background medication dose should be administered as needed every two to four hours.1 The European Association for Palliative Care (EAPC) guidelines on morphine use in cancer pain recommend the use of the equivalent of a four-hourly dose (approximately 16% of the daily dose) of usual opioid to control breakthrough cancer pain.22,42 Studies investigating various supplemental opioid formulations have, however, suggested the absence of a relationship between the effective dose of these preparations and the fixed ATC opioid dose.24,27,28,30,37 The current recommendation is therefore that each patient is titrated to a successful dose of supplemental opioid that produces adequate analgesia and minimal adverse effects.43 The need to titrate transmucosal opioid doses is the subject of much debate. For example, OTFC given in doses proportional to the basal opioid regimen has been found to be quite effective and, above all, safe in treating breakthrough pain.22,44 Further clinical studies are necessary to examine this issue.

Recommendations for the Management of Breakthrough Pain
According to the EAPC, a number of factors—such as class of drug, route of administration, dosage, patient setting, and breakthrough pain subtype—should be taken into account when selecting the appropriate medication.45 The National Pain Education Council suggest that when prescribing a drug for breakthrough pain, the ‘Four As’ of pain treatment should be considered:46

  • analgesia;
  • activities of daily living;
  • adverse events; and
  • aberrant drug-taking behaviors.

In addition, a task group of the UK and Ireland Association for Palliative Medicine made a series of 12 recommendations about certain generic strategies to manage breakthrough pain (see Table 1).47 A key point emphasized by this group was that the successful management of breakthrough pain depends on adequate reassessment of the patient, the objective of which is to determine the efficacy and tolerability of the treatment and any change in the nature of the breakthrough pain. Inadequate reassessment may lead to the continuance of ineffective and/or inappropriate treatment.47 In the absence of a validated clinical breakthrough pain assessment tool, the group recommended the use of standard pain scales to determine the response to treatment (e.g. verbal and numerical rating scales), the choice of which should be made on an individual basis.

Current Status and Future Challenges
Although the effective treatment of background and breakthrough cancer pain is a major goal for physicians involved with pain management, the possible aberrant use of opioids is a concern. There is a fear of drug misuse or abuse in:

  • vulnerable patients with positive risk factors or a past history of addiction; and
  • in the subpopulation of patients affected by both drug addiction and cancer pain, especially when immediate-release and rapid-onset opioid formulations are used.

Therefore, many chronic pain patients can be left undertreated, resulting in unrelieved pain and diminished quality of life.48 It is known that patients with a history of drug abuse and psychiatric illness are more likely to abuse opioid medication.49 The opioid risk tool and the screener and opioid assessment for patients with pain are examples of tools in the form of brief, self-administered written surveys. These can predict the level of risk for developing aberrant drug-related opioid use behaviors in patients.50,51

It has been suggested that all patients that are treated with opioids should be monitored in order to identify and manage opioid abuse. Moreover, higher-risk patients should be watched more closely and have monitored prescriptions so that appropriate pain relief is provided while aberrant drug-related behavior is prevented.52

A practical approach recommended for monitoring opioid use involves having the patient agree that opioids will be prescribed by a single provider and supplied by a single pharmacy.53 An additional suggestion is that a limited drug supply be offered to the patient, with limited refill opportunities (e.g. in the case of theft). Higher risk patients should be required to make more frequent visits for prescriptions and other important monitoring tools can be scheduled, such as random urine toxicology screening and pill counts.54Opioid drugs, when used properly, can be beneficial as tools for the management of persistent or breakthrough pain. Steps taken by the US Food and Drug Administration (FDA) and drug manufacturers include the provision of additional warnings in product labeling, implementing risk management plans, conducting inter-agency collaborations and the issuing of direct communications to both prescribers and patients. The FDA has proposed a risk evaluation and mitigation strategy (REMS) for opioids with the aim of minimizing the risks associated with opioid use while ensuring that patients who need these drugs continue to have appropriate access.55 As part of this strategy, in February 2009 the manufacturers of certain opioid pain medications, most of them extended-release products or transdermal systems, were informed that these agents would be required to have a REMS. This includes a restricted distribution program under which prescribers, pharmacies, and patients would have to register in order to prescribe, dispense, and receive this opioid, respectively.

Later in the same year, the FDA approved the first opioid with an associated REMS program: FBSF. As part of the FBSF REMS, this dosage form will only be available through a restricted distribution program called the FOCUS program.56 The development of REMS for extended-release opioid products is still the subject of much discussion and consultation between the FDA, industry, and other stakeholder groups.

Conclusion
Breakthrough pain is a heterogeneous condition and its management may involve a number of different interventions, including opioids, which have traditionally played an important role in breakthrough pain management. In some cases, optimizing ATC opioids may be helpful; however, the most common strategy is to deliver supplemental analgesia either prophylactically for predicable pain or as soon as pain starts if unpredictable.

It is clear that fast-acting opioid formulations and improved administration routes will continue to play an important role in managing breakthrough cancer pain. In particular, new formulations of fentanyl and improved delivery mechanisms hold great promise for improving quality of life for the majority of cancer patients living with the burden of breakthrough pain. The doses to be administered are still a matter of controversy in the literature and additional studies with specific designs should be conducted to settle the question. ■

Article Information:
Disclosure

Marco Pappagallo, MD, has received grants from Endo Pharmaceuticals, Inc. and the National Institutes of Health and has acted as an advisory board member involved in consulting activities for GlaxoSmithKline, Alkermes, NeurogesX, Purdue Pharma, Molteni Pharmaceuticals, Theravance, and Pfizer.

Correspondence

Marco Pappagallo, MD, Mount Sinai School of Medicine, Department of Anesthesiology, 1 Gustave L Levy Place, NY 10029. E: marco.pappagallo@mountsinai.org

Received

2010-11-25T00:00:00

References

  1. Portenoy RK, Payne D, Jacobsen P, Breakthrough pain: characteristics and impact in patients with cancer pain, Pain, 1999;81:129–34.
  2. Payne R, Recognition and diagnosis of breakthrough pain, Pain Med, 2007;(8 Suppl. 1):S3–7.
  3. Portenoy RK, Hagen NA, Breakthrough pain: definition, prevalence and characteristics, Pain, 1990;41:273–81.
  4. Bennett D, Burton A, Fishman S, Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2: Management, Pharm Therap, 2005;30:354–61.
  5. Azevedo São Leão Ferreira K, Kimura M, Jacobsen Teixeira M, The WHO analgesic ladder for cancer pain control, twenty years of use. How much pain relief does one get from using it?, Support Care Cancer, 2006;14:1086–93.
  6. McNicol E, Strassels S, Goudas L, et al., Nonsteroidal antiinflammatory drugs, alone or combined with opioids, for cancer pain: a systematic review, J Clin Oncol, 2004;22:1975–92.
  7. Chou R, Clark E, Helfand M, Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review, J Pain Symptom Manage, 2003;26:1026–48.
  8. Hwang SS, Chang VT, Kasimis B, Cancer breakthrough pain characteristics and responses to treatment at a VA medical center, Pain, 2003;101:55–64.
  9. Mercadante S, Villari P, Ferrera P, et al., Optimization of opioid therapy for preventing incident pain associated with bone metastases, J Pain Symptom Manage, 2004;28:505–10.
  10. Zeppetella G, Breakthrough pain should be distinguished from background pain, Guidelines in Practice, 2009;12:1–5.
  11. Lussier D, Huskey AG, Portenoy RK, Adjuvant analgesics in cancer pain management, Oncologist, 2004;9:571–91.
  12. Knotkova H, Pappagallo M, Adjuvant analgesics, Anesthesiol Clin, 2007;25:775–86, vi.
  13. Wiffen P, Collins S, McQuay H, et al., Anticonvulsant drugs for acute and chronic pain, Cochrane Database Syst Rev, 2005;(3):CD001133.
  14. Saarto T, Wiffen PJ, Antidepressants for neuropathic pain, Cochrane Database Syst Rev, 2005;(3):CD005454.
  15. Enting RH, Oldenmenger WH, van der Rijt CC, et al., Nitrous oxide is not beneficial for breakthrough cancer pain, Palliat Med, 2002;16:257–9.
  16. Mercadante S, Arcuri E, Tirelli W, et al., Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study, J Pain Symptom Manage, 2000;20:246–52.
  17. del Rosario MA, Martín AS, Ortega JJ, et al., Temporary sedation with midazolam for control of severe incident pain, J Pain Symptom Manage, 2001;21:439–42.
  18. Mercadante S, Villari P, Ferrera P, et al., Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose, J Pain Symptom Manage, 2004;27:352–9.
  19. Mercadante S, Villari P, Ferrera P, et al., Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine, J Pain Symptom Manage, 2006;32:175–9.
  20. Stevens RA, Ghazi SM, Routes of opioid analgesic therapy in the management of cancer pain, Cancer Control, 2000;7:132–41.
  21. Walker G, Wilcock A, Manderson C, et al., The acceptability of different routes of administration of analgesia for breakthrough pain, Palliat Med, 2003;17:219–21.
  22. Zeppetella G, Ribeiro MD, Opioids for the management of breakthrough (episodic) pain in cancer patients, Cochrane Database Syst Rev, 2006;(1):CD004311.
  23. Grape S, Schug SA, Lauer S, et al., Formulations of fentanyl for the management of pain, Drugs, 2010;70:57–2.
  24. Coluzzi PH, Schwartzberg L, Conroy JD, et al., Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR), Pain, 2001;91:123–30.
  25. Farrar JT, Cleary J, Rauck R, et al., Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients, J Natl Cancer Inst, 1998;90:611–6.
  26. Webster LR, Fentanyl buccal tablets, Expert Opin Investig Drugs, 2006;15:1469–73.
  27. Portenoy RK, Messina J, Xie F, et al., Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study, Curr Med Res Opin, 2007;23:223–33.
  28. Portenoy RK, Taylor D, Messina J, et al., A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer, Clin J Pain, 2006;22:805–11.
  29. Simpson DM, Messina J, Xie F, et al., Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study, Clin Ther, 2007;29:588–601.
  30. Slatkin NE, Xie F, Messina J, et al., Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain, J Support Oncol, 2007;5:327–34.
  31. Vasisht N, Gever LN, Tagarro I, et al., Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, openlabel, single-dose, crossover study, Clin Drug Investig, 2009;29:647–54.
  32. Rauck R, North J, Gever LN, et al., Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study, Ann Oncol, 2010;21:1308–14.
  33. Lennernäs B, Hedner T, Holmberg M, et al., Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain, Br J Clin Pharmacol, 2005;59:249–53.
  34. Rauck RL, Tark M, Reyes E, et al., Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain, Curr Med Res Opin, 2009;25:2877–85.
  35. Dale O, Hjortkjaer R, Kharasch ED, Nasal administration of opioids for pain management in adults, Acta Anaesthesiol Scand, 2002;46:759–70.
  36. Mercadante S, Radbruch L, Davies A, et al., A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial, Curr Med Res Opin, 2009;25:2805–15.
  37. Taylor D, Galan V, Weinstein SM, et al., Fentanyl pectin nasal spray in breakthrough cancer pain, J Support Oncol, 2010;8:184–90.
  38. Good P, Jackson K, Brumley D, et al., Intranasal sufentanil for cancer-associated breakthrough pain, Palliat Med, 2009;23:54–8.
  39. Zeppetella G, Impact and management of breakthrough pain in cancer, Curr Opin Support Palliat Care, 2009;3:1–6.
  40. Warren DE, Practical use of rectal medications in palliative care, J Pain Symptom Manage, 1996;11:378–87.
  41. Davis MP, Walsh D, LeGrand SB, et al., Symptom control in cancer patients: the clinical pharmacology and therapeutic role of suppositories and rectal suspensions, Support Care Cancer, 2002;10:117–38.
  42. Hanks GW, Conno F, Cherny N, et al., Morphine and alternative opioids in cancer pain: the EAPC recommendations, Br J Cancer, 2001;84:587–93.
  43. Hagen NA, Fisher K, Victorino C, et al., A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials, J Palliat Med, 2007;10:47–55.
  44. Mercadante S, Villari P, Ferrera P, et al., Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain, Br J Cancer, 2007;96:1828–33.
  45. Mercadante S, Radbruch L, Caraceni A, et al., Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care, Cancer, 2002;94:832–9.
  46. National Pain Education Council, Pain Assessment and Documentation Tool and Guidebook, Stamford, CT, National Pain Education Council, 2003.
  47. Davies AN, Dickman A, Reid C, et al., The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland, Eur J Pain, 2009;13:331–8.
  48. Kirsh KL, Whitcomb LA, Donaghy K, et al., Abuse and addiction issues in medically ill patients with pain: attempts at clarification of terms and empirical study, Clin J Pain, 2002;18:S52–60.
  49. Edlund MJ, Steffick D, Hudson T, et al., Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain, Pain, 2007;129:355–62.
  50. Webster LR, Webster RM, Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool, Pain Med, 2005;6:432–42.
  51. Akbik H, Butler SF, Budman SH, et al., Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP), J Pain Symptom Manage, 2006;32:287–93.
  52. Fishman SM, Papazian JS, Gonzalez S, et al., Regulating opioid prescribing through prescription monitoring programs: balancing drug diversion and treatment of pain, Pain Med, 2004;5:309–24.
  53. Federation of State Medical Boards of the United States, Model Policy for the use of Controlled Substances for the Treatment of Pain, DSMBUS, 2004. Available at: https://www.painpolicy.wisc.edu/domestic/model04.pdf (accessed February 14, 2011).
  54. Atluri S, Boswell MV, Hansen HC, et al., Guidelines for the use of controlled substances in the management of chronic pain, Pain Physician, 2003;6:233–57.
  55. Craig DS, The Food and Drug Administration risk evaluation and mitigation strategy, J Pain Palliat Care Pharmacother, 24:145–8.
  56. The FOCUS Program for Onsolis, Meda Pharmaceuticals, 2009. Available at: https://onsolisfocus.com/pdf/professional Overview.pdf (accessed January 14, 2011.)

Further Resources

Share this Article
Related Content In Supportive Cancer Care
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72